BIIB

AcronymDefinition
BIIBBiogen Idec, Inc. (est. 2003)
BIIBBoeing Institute of International Business (St. Louis University; St. Louis, MO)
BIIBBasic Imagery Interpretation Brief
References in periodicals archive ?
Biogen Canada, an affiliate of Biogen Inc (NASDAQ: BIIB), has received approval for Plegridy (peginterferon beta-1a) from Health Canada, it was reported on Friday.
The stock reacted sharply to the announcement of trial data details on multiple sclerosis (MS) pill BG-12, a rival of Active Biotech's laquinimod, by US Biogen Idec Inc (NASDAQ: BIIB).
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth.
Array BioPharma, a United States-based biopharmaceutical company, has signed a collaboration agreement with Biogen Idec (NASDAQ: BIIB), an American biotechnology company, it was revealed on Thursday.
Tickers featured: AMGN, ATLN.VX, AUXL, AZN, BIIB, BMY, BSTC, CORT, DYAX, EXEL, FRX, GILD, GSK, HGSI, RDEA, REGN, SGEN, SGYP.PK, SNY, SVNT, TRGT.
Sobi is currently recruiting patients for the phase III trials with its hemophilia drugs rFVIIIFc (Hemophilia A) and rFIXFc (Hemophilia B), developed in cooperation with US partner Biogen Idec Inc (NASDAQ: BIIB).
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on Biogen (BIIB) with a $250 price target following the company's MS franchise-driven second quarter beat and raise.
Tickers featured: AMGN, BIIB, BMY, CELG, CRXL, DNDN, GENZ, GILD, HGSI, JNJ, NVS, RHHBY.PK, SNY, UTHR, VRTX, YPH.F.
Lundstrom comes from US biotech company Biogen Idec Inc (NASDAQ: BIIB), where he has most recently held the position of head of Biogen Idec Hemophilia Inc.
Tickers featured: AZN, BIIB, CBST, PCYC, PDLI, ROG.VX, SGEN, SIGA, TEVA.
25 January 2010 - Swedish Orphan Biovitrum (STO: BVT) and Biogen Idec (Nasdaq: BIIB) said today that the first patient